

Human myoglobin recognition of oxygen: Dynamics of the energy landscape

Yuhong Wang, J. Spencer Baskin, Tianbing Xia, and Ahmed H. Zewail*

Laboratory for Molecular Sciences, Arthur Amos Noyes Laboratory of Chemical Physics, California Institute of Technology, Pasadena, CA 91125

Contributed by Ahmed H. Zewail, November 15, 2004

Femtosecond to nanosecond dynamics of O₂ rebinding to human WT myoglobin and its mutants, V68F and I107F, have been studied by using transient absorption. The results are compared with NO rebinding. Even though the immediate environment around the heme binding site is changed by the mutations, the picosecond geminate rebinding of oxygen is at most minimally affected. On the other hand, the V68F (E11) mutation causes drastic differences in rebinding on the nanosecond time scale, whereas the effect of the I107F (G8) mutation remains relatively small within our 10-ns time window. Unlike traditional homogeneous kinetics and molecular dynamics collisional simulations, we propose a "bifurcation model" for populations of directed and undirected dynamics on the ultrafast time scale, reflecting the distribution of initial protein conformations. The major mutation effect occurs on the time scale on which global protein conformational change is possible, consistent with transitions between the conformations of directed and undirected population playing a role in the O₂ binding. We discuss the relevance of these findings to the bimolecular function of the protein.

femtobiology | molecular recognition

Myoglobin (Mb) is considered as the hydrogen atom of biology (1), and numerous studies have been carried out to elucidate its function, the storage of oxygen in vertebrate muscle cells. In addition to storing oxygen, it can interact with other important small molecules, for example NO and carbon monoxide (2, 3), making it a prototype system for the study of molecular recognition (4). One persistent question in the study of Mb concerns the ligand recognition and its correlation to protein dynamics. X-ray study has revealed that Mb is highly compact and has to undergo conformational fluctuation to form effective "channels" for the release of the ligand (ref. 1 and references therein).

Tilton *et al.* (5) have shown that, in addition to the distal cavity next to the heme group, there are four folding defects inside the protein denoted as Xe1–Xe4 binding sites (Fig. 1 *Upper*), numbered in the decreasing order of affinity of Xe to these locations. These highly nonpolar cavities are believed to be involved in ligand migration (5). Cryogenic x-ray studies of photolysed WT and mutant carbonmonoxymyoglobin (MbCO) have indicated that CO ligand resides in the distal cavity (6, 7) as well as in the Xe4 (8, 9) and Xe1 (8, 10) sites. More recently, time-resolved x-ray studies on samples near room temperature revealed CO residence times of ligands in these sites, from 30 ns to 10 μ s for WT and recombinant mutants (11–13).

Since the pioneering work of Frauenfelder and coworkers in 1975 (14) on ligand geminate rebinding at low temperature it is known that ligand–Mb interaction involves energy landscapes of multiple conformational substates and intermediates. Two perspectives usually are discussed in the literature to account for the rebinding of O₂ and other small molecules. One of these, the multiple-site model, relates the rebinding rate to the physical location of the ligand inside the protein (15). The central theme is that discrete intermediates exist and can be mapped out on a static energy landscape. In contrast, rebinding may be controlled

by time-dependent barrier changes involving transitions among conformational substates, as manifested in the nonexponential behavior of rates (16).

Protein engineering (mutagenesis), ultrafast spectroscopy, and computational simulations all have been invoked to study dynamics in Mb. Residues located near the heme iron center and bordering the Xe4 site are demonstrated to affect the ligand nanosecond geminate rebinding as well as the overall bimolecular rebinding kinetics (8, 13, 15, 17–37). It is generally believed that mutations at these positions alter the rebinding kinetics by enhancing or restricting the ligand movement according to the multiple-site model (15). Theoretical simulations have been used to investigate the effect of mutation on ligand trajectories upon photolysis (24). Those show the ligands being confined in a place that is within 4 Å of the iron center in a mutant where Val-68 has been mutated to phenylalanine (V68F mutant). This space restriction has been proposed to be the reason for the observed high geminate rebinding for the V68F mutant.

Champion and coworkers (38) have carefully studied, with femtosecond time resolution, the transient absorption dynamics of O₂-bound native horse heart Mb and reported a geminate recombination lifetime of ≈ 5 ps, similar to the 6.4 ± 2 -ps geminate recombination lifetime reported from an earlier picosecond study (39). For the mutants, no femtosecond O₂ binding studies have been reported. Experiments on the sperm whale V68F/O₂ system have been conducted with 35-ps laser pulses (30), but these could not resolve the ultrafast recombination process. Because the picosecond geminate rebinding is the ultimate step to form the protein–ligand bond, information in this time regime is critical for the understanding of the elementary steps of molecular recognition.

From this group, an earlier effort focused on the dynamics, kinetics, and thermodynamics of molecular recognition of O₂ by a Mb and hemoglobin mimic, cobalt picket-fence porphyrin (40, 41). In this article, we report a study of oxygen recognition in real proteins, the recombinant human Mb and its mutants, from the femtosecond to nanosecond regime. We have chosen the mutants V68F and I107F (in which isoleucine at residue 107 is replaced by phenylalanine), which alter two of the residues that border the Xe4 site (Fig. 1 *Lower*). With femtosecond resolution, we were able to probe the mutant behavior with an extended window up to 10 ns. From the results, we propose a bifurcation dynamics model for which direct O₂ rebinding occurs for some conformational populations on the femtosecond to picosecond time scales before protein conformational fluctuation can occur. This directed ultrafast recombination contrasts with the undirected diffusive ligand migration on the nanosecond to microsecond time scale.

Materials and Methods

Biochemistry: Protein Expression and Mutants. The synthetic gene for human WT Mb, which carries G80A and C110A mutations,

Abbreviations: Mb, myoglobin; MbCO, carbonmonoxymyoglobin; MbO₂, oxymyoglobin; MbNO, nitrosylmyoglobin; deoxyMb, deoxymyoglobin.

*To whom correspondence should be addressed. E-mail: zewail@caltech.edu.

© 2004 by The National Academy of Sciences of the USA

Table 1. Observed rates and fractions for O₂ geminate rebinding to human WT, V68F, and I107F Mbs from transient absorption at 436 nm

Mb	This work				Literature*	
	τ_1 , ps	$\Gamma_{\text{esc(ps)}}$, %	τ_2 , ns	$\Gamma_{\text{esc(ns)}}$, %	τ_2 , ns	$\Gamma_{\text{esc(ns)}}$, %
WT	6 ± 1	70 ± 6			55 [†]	55
V68F	6 ± 1	70 ± 6	2.7 ± 0.6 [‡]	9 ± 5		
I107F	6 ± 1	70 ± 6			45	27

$\Gamma_{\text{esc(ps)}}$ and $\Gamma_{\text{esc(ns)}}$ are the escape fractions in the picosecond and nanosecond regime. These are the ratios between the offset and the initial value of the transient absorption in the appropriate time range.

*Data are from ref. 33.

[†]The WT transient could be fit best with two nanosecond components with lifetimes of 27 and 135 ns.

[‡]The fit of all V68F nanosecond transients improved with the use of two exponential components and an offset, but fit parameters were not well determined in such fitting. See text.

MbCO, MbO₂, and MbNO. For MbO₂, a 4–to 6-ps decay component was observed at all probe wavelengths and assigned as primarily caused by geminate recombination of oxygen to the ground state of the unbound protein for several reasons: (i) the 4–to 6-ps decay component did not appear in the transient absorption of deoxyMb; (ii) it did not appear in the transient absorption of MbCO, which has no picosecond geminate rebinding; (iii) it was observed with opposing signs when probing at 418 nm, the Soret band of MbO₂, and 438 nm, the deoxyMb Soret band; and (iv) it was absent when probing at the isosbestic points of the Mb/O₂ spectrum. The amplitude of this component relative to the residual ΔA changed with probe wavelength, which would not occur if it was totally caused by geminate recombination at all wavelengths, but its fraction was smallest for probing at the deoxyMb Soret band, as in our experiments. Accordingly, ΔA is considered to reflect the amount of unligated Mb over all time ranges, and as such, the experimental geminate rebinding rates and the fractions of ligand escaping on the picosecond and nanosecond time scales, from this work and the literature, are given in Table 1.

The most significant observations made in this work can be summarized as follows: (i) As shown schematically in Fig. 5 *Top*, with the newly femtosecond-resolved transients of MbO₂ reported here, the response to photolysis of the WT and mutants can be fully characterized, revealing that behaviors differ distinctly among mutants on long time scales, whereas on the ultrafast time scale they are essentially the same. The overall behavior is reflective of the dynamics of O₂ binding and unbinding. (ii) Although the mutation at position 68 (Fig. 1 *Bottom*) introduces a structural blockage, through the phenyl group, in the immediate vicinity of the iron center, the picosecond behavior is not greatly altered. This response could not be observed in previous studies of the V68F mutant because of the 35-ps pulses used (30). (iii) The ultrafast response for the I107F mutant is likewise nearly the same as for the WT. (iv) On the nanosecond time scale, V68F mutation enhances the rates by more than an order of magnitude, qualitatively consistent with previous work on sperm whale Mb using 9- to 17-ns pulses (24, 30). For I107F, the nanosecond response is on a much longer time scale. (v) Finally, we repeated the same experiments with NO instead of O₂ and obtained results in qualitative agreement with other work at different pump and probe wavelengths for WT and V68F sperm whale Mb (31), WT horse heart Mb (39), and WT human Mb (42). Our measured transient for WT over early time (Fig. 4 *Upper*) is very similar to that recorded for WT horse heart MbNO over the same time range and with the similar pump and probe wavelengths of 400 and 438 nm, respectively (38), as evidenced by a comparison of parameters obtained when fitting this restricted time range as a simple biexponential: 12.2 ps, 37% and 187 ps, 63% for our data vs. 13.0 ps, 35% and 190 ps, 65% in ref. 38.

With these observations and comparisons, the following picture of the protein dynamics and energy landscape emerges. After the femtosecond initiation of O₂ release, the ligand first dwells at a distal site close to the iron center, in a cavity with direct access to Xe4 (see Fig. 1). Then it could either geminately rebound or escape to sites of minimum energy, e.g., Xe4, identified by x-ray diffraction as one collection site for CO after photolysis of MbCO (11, 12). The observed geminate recombination is




Fig. 5. Dynamics and landscapes for Mb recognition of oxygen. (Top) Illustration of the time evolution of 436-nm transient absorbance of WT (blue), I107F (green), and V68F (red) MbO₂ after femtosecond photolysis. The positive signal change, which is proportional to the population of unligated Mb, decays on multiple time scales as the protein rebinds O₂. (Middle) Schematic free energy landscapes for O₂ migration away from the heme binding site in WT (blue) and V68F (red) Mb. (Left) Picosecond, directed dynamics (unaffected by mutation). (Right) Nanosecond, undirected dynamics (affected by mutation). (Bottom) Schematic representation of a bifurcation of Mb conformations associated with directed (Left) and undirected (Right) ultrafast dynamics. GR, geminate recombination.

ultrafast (≈ 6 ps), and if it is driven by the kinetics of a homogeneous protein ensemble, then the V68F mutant (which changes the environment of the Xe4 site) should result in a significant change of the rate and the fraction rebound, contrary to our observation. For example, the blue energy landscape in Fig. 5 *Middle Right* is illustrative of one in which the forward migration to Xe4 would be faster than rebinding, consistent with the observed 70/30 escape vs. rebinding branching ratio. Because the V68F mutation reduces the Xe4 cavity to half of the space in WT (red potential curve in Fig. 5), the escape process is hindered, which should enhance the rebinding process. The molecular dynamics simulations using the locally enhanced sampling method predicted such a mutant effect (24). In those simulations, for V68F mutant, the phenylalanine at residue 68 occupies the same spot in the Xe4 cavity in which ligands gather in the WT. Consequently, the ligands are forced to reside in the primary distal site, causing more collisions between the ligands and the iron center.

The unchanging observed rate and fraction of the picosecond rebinding in our experiments would require, for a homogeneous system, a constant value for both the forward rate (to Xe4) and the rebinding rate, contradicting the above predictions of the V68F mutant effect. To account for the discrepancy, we propose that the ultrafast primary step follows the dynamics of the bifurcation model, which was found to be significant in ultrafast chemical and biological reactions (ref. 43 and references therein), such as DNA gating of electron transfer (44, 45). In this case, because of protein conformations with low free energy barriers to recombination, the directed population will rebound within the first few ps (Fig. 5 *Middle Left* and *Bottom Left*), whereas the undirected population will be in conformations capable of recombination after thermal and intramolecular motions on a longer time scale (Fig. 5 *Middle Right* and *Bottom Right*). Because the escape fraction is determined by the conformational bifurcation rather than the competition between forward and backward rates, as long as recombination is highly favored in the directed population of the WT, the obstruction of the Xe4 cavity in V68F will have little effect on the ultrafast time scale (Fig. 5 *Middle Left*).

The reasoning given above based on competition between forward and backward rates on a static energy landscape also should apply when photolysis-initiated local conformational dynamics (e.g., motion of the Fe atom relative to the heme plane) are important in the picosecond process (46, 47). That is, if mutation causes the pronounced change in the ligand/Fe collision frequency that is predicted by molecular dynamics simulations for V68F (24), the probability of reforming the ligand-Fe bond must change accordingly and at least the picosecond escape fraction would clearly reflect this change in a homogeneous sample.

This bifurcation picture raises an important point about the nature of the energy landscape and trajectory of motions. The instantaneous dissociation of O₂ generates a nonequilibrium protein ensemble that then evolves toward equilibrium. On the femtosecond to picosecond time scale, the protein is essentially a frozen matrix and only small and local conformational changes (lower level of conformational tiers) may be involved. The directed geminate recombination takes place on one family of conformations that is adapted to ensure efficient reformation of the metal-ligand bond on a static or minimally fluctuating landscape, and we observe no change of rates or fractions with mutation.

Larger and global motions in the protein occur at longer time. Those motions involve transitions of higher tiers of conformational structures. On such time scales, the trajectories visit a large phase space and the landscape fluctuations play a role. Trajectories are the result of many collisions in the cavity and barriers and wells can fluctuate. For example, the landscape may evolve

from one of undirected dynamics, as in Fig. 5 *Right*, to that in Fig. 5 *Left*, which will direct the ligand to immediate bond formation. In such a situation, a mutant effect on the protein global fluctuation will alter the rebinding dynamics. Indeed, the observed delayed mutant effect on recombination could be an indication of the time scale of protein global dynamics and thermal fluctuations and how they are affected by the mutations. For MbCO, time-resolved x-ray studies (11, 12) and spectroscopic studies (46, 48, 49) have indicated a wide range of time scales of photolysis-driven global conformational changes, from hundreds of picoseconds to microseconds. On the other hand, modification of the local energy landscape by steric hindrance undoubtedly also will have its effect on nanosecond and longer time dynamics. It is noteworthy that, even though residue 107 is located close to residue 68, mutant I107F does not cause a significant deviation from the WT as V68F. This may be because these two spatially close residues are involved in the global dynamics differently, perhaps because they are on different helices.

When O₂ rebinds from the solvent bimolecularly, it can be expected to be subject to the same processes as when photolytically released. O₂ must reenter the distal cavity, possibly after passage through other intermediate states. On the time scale of this migration, protein conformational dynamics will clearly be important, as the energy landscape and barrier heights fluctuate. The V68F mutation slows down the initial process by a factor of 13 relative to WT (50), whereas the I107F mutation again has only a moderate effect ($\approx 35\%$ rate reduction) (33). The magnitudes of these changes are consistent with the influence of these specific mutations on protein dynamics inferred from the picture of dynamic control on the nanosecond rates.

In the Mb mimic, cobalt picket-fence porphyrin with methylimidazole base (B-CoP), analysis of the global rebinding dynamics showed that an intermediate B-CoP \cdots O₂ state was formed that had only a $\approx 2\%$ probability of going on to form the ligand-metal bond (40). In addition, the ultrafast dynamics of this system showed no geminate recombination of O₂ (41). Replacement of the cobalt center with iron results in a much higher affinity for O₂ (51, 52) and 43% geminate recombination with a 25-ps lifetime (53). For the three Mb mutants studied here, with 30% recombination on the picosecond time scale, recombination from intermediate states on the nanosecond time scale ranges from 45% to 91% [$1 - \Gamma_{esc(ns)}$ from Table 1]. These results all are consistent with the concept that the existence of conformations leading to directed ultrafast dynamics enhance the efficiency of the binding function, even in a relatively simple system like the picket fence.

Recombination to WT Mb on the picosecond time scale is much more efficient for NO than for O₂. Because the intrinsic chemical reactivity, orientation when the ligand is bound to heme, and electrostatic and hydrogen-bonding interaction with the protein moiety all are so different for these two ligands, a difference in the binding process is not surprising. In contrast to O₂, the V68F mutant effect for NO is dramatic within the first 10 ps of photolysis (Fig. 4). This behavior is consistent with the expectations from homogeneous kinetics and local structural changes, as modeled in the above-mentioned molecular dynamics simulations (24), and the role of conformations such as those associated with directed dynamics for O₂ may be very different for NO because of the different binding. More recent theoretical work on NO rebinding using the reactive molecular dynamics method shows that on this short time scale fluctuations in the immediate vicinity of the binding site control the NO nonexponential rebinding (47).

Conclusion

With femtosecond time resolution, the picosecond to nanosecond geminate rebinding dynamics of oxygen to Mb WT, V68F,

and I107F mutants has been studied. The lack of a pronounced mutation effect on the initial rebinding for either mutant shows that this process is kinetically isolated from the distal pocket environment through which the ligand moves on the nanosecond time scale. The bifurcation that allows this isolation is understood in terms of a distribution of conformational structures, with one set of conformations leading to directed O₂-Fe bond formation without sampling a large phase space. These structures may be functionally important, with protein global conformational fluctuations into such structures guiding the O₂ to efficient binding once it has reached the distal cavity from the

solvent. The fact that V68F mutation causes a drastic effect on rebinding dynamics on the time scale of protein global fluctuation is consistent with this concept of directed populations. The existence of conformations optimized for directed bonding in MbO₂ should be important for an efficient biological function (43, 54, 55).

We acknowledge the contribution of Dr. Qing-Bin Lu (California Institute of Technology) in developing the experimental apparatus used for the measurements reported here. This work was supported by the National Science Foundation.

1. Frauenfelder, H., McMahon, B. H. & Fenimore, P. W. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 8615–8617.
2. Olson, J. S. & Phillips, G. N. (1996) *J. Biol. Chem.* **271**, 17593–17596.
3. Gibson, Q. H. (1989) *J. Biol. Chem.* **264**, 20155–20158.
4. Springer, B. A., Sligar, S. G., Olson, J. S. & Phillips, G. N. (1994) *Chem. Rev.* **94**, 699–714.
5. Tilton, R. F., Kuntz, I. D. & Petsko, G. A. (1984) *Biochemistry* **23**, 2849–2857.
6. Schlichting, I., Berendzen, J., Phillips, G. N. & Sweet, R. M. (1994) *Nature* **371**, 808–812.
7. Teng, T. Y., Schildkamp, W., Dolmer, P. & Moffat, K. (1994) *J. Appl. Crystallogr.* **27**, 133–139.
8. Ostermann, A., Waschipyk, R., Parak, F. G. & Nienhaus, G. U. (2000) *Nature* **404**, 205–208.
9. Brunori, M., Vallone, B., Cutruzzola, F., Travaglini-Allocatelli, C., Berendzen, J., Chu, K., Sweet, R. M. & Schlichting, I. (2000) *Proc. Natl. Acad. Sci. USA* **97**, 2058–2063.
10. Chu, K., Vojtchovsky, J., McMahon, B. H., Sweet, R. M., Berendzen, J. & Schlichting, I. (2000) *Nature* **403**, 921–923.
11. Srajer, V., Ren, Z., Teng, T. Y., Schmidt, M., Ursby, T., Bourgeois, D., Pradervand, C., Schildkamp, W., Wulff, M. & Moffat, K. (2001) *Biochemistry* **40**, 13802–13815.
12. Schotte, F., Lim, M. H., Jackson, T. A., Smirnov, A. V., Soman, J., Olson, J. S., Phillips, G. N., Wulff, M. & Anfirrud, P. A. (2003) *Science* **300**, 1944–1947.
13. Bourgeois, D., Vallone, B., Schotte, F., Arcovito, A., Miele, A. E., Sciarra, G., Wulff, M., Anfirrud, P. & Brunori, M. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 8704–8709.
14. Austin, R. H., Beeson, K. W., Eisenstein, L., Frauenfelder, H. & Gunsalus, I. C. (1975) *Biochemistry* **14**, 5355–5373.
15. Gibson, Q. H., Regan, R., Elber, R., Olson, J. S. & Carver, T. E. (1992) *J. Biol. Chem.* **267**, 22022–22034.
16. Frauenfelder, H., Sligar, S. G. & Wolynes, P. G. (1991) *Science* **254**, 1598–1603.
17. Nienhaus, K., Deng, P. C., Kriegl, J. M. & Nienhaus, G. U. (2003) *Biochemistry* **42**, 9633–9646.
18. Kriegl, J. M., Nienhaus, K., Deng, P. C., Fuchs, J. & Nienhaus, G. U. (2003) *Proc. Natl. Acad. Sci. USA* **100**, 7069–7074.
19. Nienhaus, G. U. & Nienhaus, K. (2002) *J. Biol. Phys.* **28**, 163–172.
20. Lamb, D. C., Nienhaus, K., Arcovito, A., Draghi, F., Miele, A. E., Brunori, M. & Nienhaus, G. U. (2002) *J. Biol. Chem.* **277**, 11636–11644.
21. Uchida, T., Ishimori, K. & Morishima, I. (2000) *J. Biol. Chem.* **275**, 30309–30316.
22. Adachi, S., Sunohara, N., Ishimori, K. & Morishima, I. (1992) *J. Biol. Chem.* **267**, 12614–12621.
23. Carver, T. E., Brantley, R. E., Singleton, E. W., Arduini, R. M., Quillin, M. L., Phillips, G. N. & Olson, J. S. (1992) *J. Biol. Chem.* **267**, 14443–14450.
24. Quillin, M. L., Li, T. S., Olson, J. S., Phillips, G. N., Dou, Y., Ikedasaito, M., Regan, R., Carlson, M., Gibson, Q. H., Li, H. Y. & Elber, R. (1995) *J. Mol. Biol.* **245**, 416–436.
25. Smerdon, S. J., Dodson, G. G., Wilkinson, A. J., Gibson, Q. H., Blackmore, R. S., Carver, T. E. & Olson, J. S. (1991) *Biochemistry* **30**, 6252–6260.
26. Dou, Y., Admiraal, S. J., Ikedasaito, M., Krzywdka, S., Wilkinson, A. J., Li, T. S., Olson, J. S., Prince, R. C., Pickering, I. J. & George, G. N. (1995) *J. Biol. Chem.* **270**, 15993–16001.
27. Ikedasaito, M., Dou, Y., Yonetani, T., Olson, J. S., Li, T. S., Regan, R. & Gibson, Q. H. (1993) *J. Biol. Chem.* **268**, 6855–6857.
28. Krzywdka, S., Murshudov, G. N., Brzozowski, A. M., Jaskolski, M., Scott, E. E., Klizas, S. A., Gibson, Q. H., Olson, J. S. & Wilkinson, A. J. (1998) *Biochemistry* **37**, 15896–15907.
29. Nienhaus, K., Deng, P. C., Olson, J. S., Warren, J. J. & Nienhaus, G. U. (2003) *J. Biol. Chem.* **278**, 42532–42544.
30. Carver, T. E., Rohlf, R. J., Olson, J. S., Gibson, Q. H., Blackmore, R. S., Springer, B. A. & Sligar, S. G. (1990) *J. Biol. Chem.* **265**, 20007–20020.
31. Kholodenko, Y., Gooding, E. A., Dou, Y., Ikeda-Saito, M. & Hochstrasser, R. M. (1999) *Biochemistry* **38**, 5918–5924.
32. Nienhaus, K., Deng, P. C., Kriegl, J. M. & Nienhaus, G. U. (2003) *Biochemistry* **42**, 9647–9658.
33. Ishikawa, H., Uchida, T., Takahashi, S., Ishimori, K. & Morishima, I. (2001) *Biophys. J.* **80**, 1507–1517.
34. Rector, K. D., Rella, C. W., Hill, J. R., Kwok, A. S., Sligar, S. G., Chien, E. Y. T., Dlott, D. D. & Fayer, M. D. (1997) *J. Phys. Chem. B* **101**, 1468–1475.
35. Rector, K. D., Engholm, J. R., Hill, J. R., Myers, D. J., Hu, R., Boxer, S. G., Dlott, D. D. & Fayer, M. D. (1998) *J. Phys. Chem. B* **102**, 331–333.
36. Rector, K. D. & Fayer, M. D. (1999) *Laser Chem.* **19**, 19–34.
37. Suzuki, T., Watanabe, Y., Nagasawa, M., Matsuoka, A. & Shikama, K. (2000) *Eur. J. Biochem.* **267**, 6166–6174.
38. Ye, X., Demidov, A. & Champion, P. M. (2002) *J. Am. Chem. Soc.* **124**, 5914–5924.
39. Walda, K. N., Liu, X. Y., Sharma, V. S. & Magde, D. (1994) *Biochemistry* **33**, 2198–2209.
40. Zou, S. Z., Baskin, J. S. & Zewail, A. H. (2002) *Proc. Natl. Acad. Sci. USA* **99**, 9625–9630.
41. Steiger, B., Baskin, J. S., Anson, F. C. & Zewail, A. H. (2000) *Angew. Chem. Int. Ed.* **39**, 257–260.
42. Petrich, J. W., Lambry, J. C., Balasubramanian, S., Lambright, D. G., Boxer, S. G. & Martin, J. L. (1994) *J. Mol. Biol.* **238**, 437–444.
43. Zewail, A. H. (2000) *Angew. Chem. Int. Ed.* **39**, 2587–2631.
44. Wan, C. Z., Fiebig, T., Kelley, S. O., Treadway, C. R., Barton, J. K. & Zewail, A. H. (1999) *Proc. Natl. Acad. Sci. USA* **96**, 6014–6019.
45. Bruinsma, R., Grüner, G., D’Orsogna, M. R. & Rodnick, J. (2000) *Phys. Rev. Lett.* **85**, 4393–4396.
46. Lim, M. H., Jackson, T. A. & Anfirrud, P. A. (1993) *Proc. Natl. Acad. Sci. USA* **90**, 5801–5804.
47. Meuwly, M., Becker, O. M., Stote, R. & Karplus, M. (2002) *Biophys. Chem.* **98**, 183–207.
48. Xie, X. L. & Simon, J. D. (1991) *Biochemistry* **30**, 3682–3692.
49. Goodno, G. D., Astinov, V. & Miller, R. J. D. (1999) *J. Phys. Chem. A* **103**, 10630–10643.
50. Egeberg, K. D., Springer, B. A., Sligar, S. G., Carver, T. E., Rohlf, R. J. & Olson, J. S. (1990) *J. Biol. Chem.* **265**, 11788–11795.
51. Collman, J. P., Brauman, J. I., Doxsee, K. M., Halbert, T. R., Hayes, S. E. & Suslick, K. S. (1978) *J. Am. Chem. Soc.* **100**, 2761–2766.
52. Collman, J. P. & Fu, L. (1999) *Acc. Chem. Res.* **32**, 455–463.
53. Grogan, T. G., Bag, N., Traylor, T. G. & Magde, D. (1994) *J. Phys. Chem.* **98**, 13791–13796.
54. McCammon, J. A. (2000) in *Simplicity and Complexity in Proteins and Nucleic Acids*, eds. Frauenfelder, H., Deisenhofer, J. & Wolynes, P. G. (Dahlem Univ. Press, Berlin), pp. 193–198.
55. Karplus, M. (2000) in *Simplicity and Complexity in Proteins and Nucleic Acids*, eds. Frauenfelder, H., Deisenhofer, J. & Wolynes, P. G. (Dahlem Univ. Press, Berlin), pp. 139–177.